Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

RNAi

This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal. Bolsters pipeline ahead of Soliris patent protection loss. ... Alexion has signed a deal with RNAi specialists Dicerna to discover therapies for complement-mediated diseases.

Latest news

  • Alnylam seeks fast-track filing with biomarker data Alnylam seeks fast-track filing with biomarker data

    Alnylam is set to file its next RNAi drug candidate givosiran with regulators after producing strong phase 3 data. ... After 15 years building its RNAi ‘gene silencing’platform, the Cambridge, Massachusetts based biotech gained its first US and EU

  • Alnylam claims first RNAi approval from FDA for patisiran Alnylam claims first RNAi approval from FDA for patisiran

    Alnylam claims first RNAi approval from FDA for patisiran. After years of ups and downs, triumph for gene-silencing tech. ... RNAi drugs are used to block gene expression, binding to the messenger RNA that corresponds to a defective gene and switching

  • The year of the blockbuster The year of the blockbuster

    UK, the projected blockbuster list includes four biologicals, one  RNAi-based drug, one vaccine  and six small molecules. ... It is expected to become the first FDA-approved RNAi therapeutic following Alnylam’s completion of its new drug application

  • Optimum wins Silence Therapeutics account Optimum wins Silence Therapeutics account

    London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics.

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    use to 140, 000 patients in its licensed territories – but particularly for Alnylam which has seen its RNAi platform come under scrutiny in recent months.

More from news
Approximately 7 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    This has been Alnylam’s story over the past 16 years, as it built on Andrew Fire and Craig Mello’s Nobel prize winning discovery that naturally occurring RNAi “silences”genes, ... Its RNAi technology can be used to target any gene expressed in

  • Boosting pharma’s metabolic rate Boosting pharma’s metabolic rate

    New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.

  • Deal Watch September 2016 Deal Watch September 2016

    800. Arrowhead / Amgen. Licences. 2 agreements to develop and commercialise RNAi therapies in CVS disease, upfront payments of $35m, $21.5m in equity plus $617m in option payments. ... 95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's

  • Pharma deals during January 2014 Pharma deals during January 2014

    Our table includes four RNAi-based deals, so are we seeing a resurgence of interest in this field? ... The deal comprised a range of RNAi assets including pre-clinical candidates, IP and delivery technologies.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Bruce Peacock joins Dicerna from Ophthotech Bruce Peacock joins Dicerna from Ophthotech

    Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

  • Silence appoints chief medical officer Silence appoints chief medical officer

    These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Quick links

Infographics

Multimedia